Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11445080 | 0.93 | TSHR (0.34) | DNM1ALDH1A1CNR1CNR2USP2 | |
| SCHEMBL27368035 | 0.83 | DNM1 (0.41) | DNM1ALDH1A1CNR1CNR2USP2 | |
| SCHEMBL1095934 | 0.79 | DNM1 (0.45) | DNM1ALDH1A1CNR1CNR2USP2 | |
| SCHEMBL27486635 | 0.79 | CES2 (0.38) | DNM1ALDH1A1CNR1CNR2USP2 | |
| SCHEMBL6033006 | 0.79 | DNM1 (0.42) | DNM1USP2SPHK1HTTLPAR1 | |
| SCHEMBL24593010 | 0.78 | ODC1 (0.33) | — | |
| SCHEMBL27925080 | 0.78 | SPHK1 (0.42) | DNM1USP2SPHK1HTT | |
| SCHEMBL27695365 | 0.78 | SPHK1 (0.42) | DNM1USP2SPHK1HTT | |
| SCHEMBL1978801 | 0.77 | DNM1 (0.48) | DNM1USP2SPHK1HTTLPAR1 | |
| SCHEMBL23038765 | 0.77 | DNM1 (0.48) | DNM1USP2SPHK1HTTLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8920591-B2 | Process for producing electrically conductive bonds between solar cells | BASF SE (DE) | 2014-12-30 | — | — | US | disclosed |
| EP-2537188-A1 | PROCESS FOR PRODUCING ELECTRICALLY CONDUCTIVE BONDS BETWEEN SOLAR CELLS | BASF SE (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20120312467-A1 | PROCESS FOR PRODUCING ELECTRICALLY CONDUCTIVE BONDS BETWEEN SOLAR CELLS | BASF SE (DE) | 2012-12-13 | — | — | US | disclosed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| WO-2011101788-A1 | PROCESS FOR PRODUCING ELECTRICALLY CONDUCTIVE BONDS BETWEEN SOLAR CELLS | BASF SE (DE) | 2011-08-25 | — | — | WO | disclosed |
| US-7981642-B2 | Polymer extraction methods | METABOLIX, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2266979-A1 | 2-morpholino-4-pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-7795376-B2 | Single solvent polymer extraction methods | METABOLIX INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100197885-A1 | POLYMER EXTRACTION METHODS | METABOLIX, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100196997-A1 | POLYMER EXTRACTION METHODS | METABOLIX, INC. | 2010-08-05 | — | — | US | disclosed |
| US-7713720-B2 | Polymer extraction methods | METABOLIX INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100016544-A1 | SINGLE SOLVENT POLYMER EXTRACTION METHODS | CJ CHEILJEDANG CORPORATION (KR) | 2010-01-21 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20070278157-A1 | Polymer Extraction Methods | METABOLIX INC. (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1789414-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | DNM1 172/4885ALDH1A1 3276/4885CNR1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.